Indian Pharma market to expand by 8-9 percent in FY26: Report

Further, the moving annual total (MAT) -- or the 12-month rolling sales of overall pharma products -- saw an 8.1 per cent surge in February, the report said. Cardiac therapies outperformed growth in the pharma market with 10.8 per cent growth in MAT and a 13.7 per cent increase in monthly market share. This was followed by gastroenterology, neurology/Central Nervous System, and dermatology.

On the other hand, anti-infectives, respiratory, and gynaecology therapies saw a weak growth in February, the report said.

Meanwhile, another recent report showed that the pharma sector in the country is witnessing rapid production growth. The Indian pharma sector has grown at 8 per cent CAGR and has also seen a 9 per cent increase in export rates in 2024, according to the report by McKinsey & Company.

Expanding its capabilities in APIs and biotechnology, it has grown at 8 per cent CAGR, twice the global average. The country also emerged as the world’s largest supplier of generic medicines, with a 9 per cent pharma export growth rate, nearly double the global average, the report said.